Thermo Fisher Scientific, a global leader in serving science, has announced a strategic partnership with Datavant to improve how real-world data connects with clinical research. The collaboration will help pharmaceutical and biotech companies generate stronger evidence more efficiently and enable faster insights into patient outcomes.
Health Technology Insights: ConcertAI Uses Agentic AI to Accelerate Clinical Trials
Through this partnership, Thermo Fisher’s PPD clinical research business will use Datavant’s platform to securely link and analyze patient-level data from a variety of sources, including randomized clinical trials, PPD CorEvitas Clinical Registries, and PPD Evidera solutions. Datavant offers privacy-preserving tokenization and data linkage across more than 350 real-world data partners and 80,000 U.S. hospitals and clinics.
Health Technology Insights: NuvemRx Acquires par8o to Expand Specialty Care Capabilities
Integrating Datavant’s encrypted token technology into Thermo Fisher’s real-world data infrastructure will give clients access to enriched, de-identified datasets, consented electronic medical record data, and advanced analytics. This supports more connected studies, improved patient recruitment, and faster evidence generation. The effort builds on Thermo Fisher’s broader investments in digital and AI-driven innovation to enhance clinical research outcomes.
Karen Kaucic, M.D., president of patient and advisory services and chief medical officer for clinical research at Thermo Fisher Scientific, explained that privacy-protected, seamless data connectivity is essential for advancing evidence generation. She said the collaboration provides a more efficient research experience for clients while maintaining patient privacy and data security. Arnaub Chatterjee, GM and President of Life Sciences at Datavant, added that combining Datavant’s data linkage technology with Thermo Fisher’s clinical expertise brings richer, connected patient data into research workflows and reduces barriers across the clinical trial and real-world evidence continuum.
Krishna Cheriath, vice president and head of digital and AI for biopharma services at Thermo Fisher Scientific, said this partnership is a major step in digital transformation. He noted that it enables faster insights, supports better patient outcomes, and strengthens Thermo Fisher’s leadership in real-world evidence, registry, and observational study services. This collaboration reflects the company’s ongoing commitment to integrating advanced technology with clinical research to drive innovation for life sciences customers.
Health Technology Insights: Ambry Genetics Hits One Million RNA-Based Diagnostic Tests
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
